Anti-carbamylated protein antibodies are associated with early abatacept response in rheumatoid arthritis Comment on: Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept

We read the article by Kumar et al., which is the first to address the association between anti-carbamylated protein antibodies (anti-CarP) and the response to abatacept (ABA) in rheumatoid arthritis (RA), with great interest. The most striking findings were the better response (a significant reduct...

Descripción completa

Detalles Bibliográficos
Autores: Castellanos-Moreira, R., Gómez, A., Haro Villar, Isabel, Ruiz-Esquide, V., Marsal, V., Sanmartí, Raimon
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/251648
Acceso en línea:http://hdl.handle.net/10261/251648
Access Level:acceso abierto
Palabra clave:Anti-carbamylated protein antibodies
Descripción
Sumario:We read the article by Kumar et al., which is the first to address the association between anti-carbamylated protein antibodies (anti-CarP) and the response to abatacept (ABA) in rheumatoid arthritis (RA), with great interest. The most striking findings were the better response (a significant reduction in δ-DAS28-PCR) to ABA in anti-CarP positive patients and a reduction in anti-CarP levels. No differences in the therapeutic response were found when analyzed according to ACPA nor rheumatoid factor status (1).